You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,629,317


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,629,317
Title:Non-human transgenic mammal for the constant region of the class a human immunoglobulin heavy chain and applications thereof
Abstract: The invention relates to a non-human transgenic mammal with an IgH locus modified by replacement of the switching sequence S.mu. with all or part of a transgene comprising the gene C.alpha. of a class A human immunoglobulin, including at least the exon, coding for the CH3 domain and the membrane exon and the applications of the above for the production of humanized class IgA antibodies.
Inventor(s): Cogne; Michel (Isle, FR), Sirac; Christophe (Limoges, FR), Bardel; Micael (Couzeix, FR), Decourt; Catherine (Rilhac-Rancon, FR), Le Morvan; Caroline (Vicq-sur-Breuil, FR)
Assignee: Centre National de la Recherche Scientifique (Paris Cedex, FR) Universite de Limoges (Limoges Cedex, FR)
Application Number:10/577,061
Patent Claims:1. A transgenic mouse, wherein an endogenous IgH locus comprises replacement of its switch sequence S.mu. with a transgene consisting essentially of a human class A immunoglobulin heavy chain constant region gene C.alpha. or a segment of said C.alpha. gene comprising at least an exon encoding the CH3 domain and a membrane exon, wherein said transgenic mouse produces chimeric immunoglobulins A whose heavy chains comprise a mouse variable region and a human constant region or a segment thereof comprising at least the CH3 domain, and wherein said transgenic mouse produces no mouse immunoglobulins M.

2. The transgenic mouse of claim 1, which is homozygous for said modified IgH locus.

3. The transgenic mouse of claim 1, wherein said transgene consists of the entire C.alpha. gene.

4. The transgenic mouse of claim 1, wherein said transgene consists of the segment of the C.alpha. gene comprising the exon encoding the CH3 domain and the membrane exon.

5. The transgenic mouse of claim 1, wherein said C.alpha. gene is the C.alpha.1 gene.

6. The transgenic mouse of claim 1, which further comprises another transgene encoding a human immunoglobulin light chain.

7. The transgenic mouse of claim 6, wherein said light chain is a kappa light chain.

8. The transgenic mouse of claim 6, wherein said transgene which encodes a human immunoglobulin kappa light chain, further comprises the intronic activator E.mu. upstream of a DNA sequence encoding said human immunoglobulin kappa light chain and the palindrome hs3a/hs1,2/hs3b downstream of said DNA sequence.

9. The transgenic mouse of claim 8, wherein said transgene is under the control of the promoter of the human immunoglobulin heavy chain.

10. The transgenic mouse of claim 6, which is dizygous for said transgene.

11. The transgenic mouse of claim 6, further comprising an inactivated endogenous immunoglobulin kappa light chain locus.

12. The transgenic mouse of claim 11, which is homozygous for said inactivated endogenous immunoglobulin kappa light chain locus.

13. The transgenic mouse of claim 1, further comprising an inactivated endogenous J chain gene.

14. The transgenic mouse of claim 13, which is homozygous for said inactivated endogenous J chain gene.

15. The transgenic mouse of claim 13, which further comprises another transgene encoding a human immunoglobulin J chain gene.

16. The transgenic mouse of claim 1, wherein said: a) endogenous mouse IgH locus comprises the replacement of its switch sequence S.mu. with the entire human class A immunoglobulin heavy chain constant region gene C.alpha.1, and b) which transgenic mouse further comprises a human kappa light chain transgene comprising a V.kappa.I gene rearranged with a J.kappa.5 gene, a J.kappa.-C.kappa. intron and a C.kappa. gene, under the transcriptional control of the human heavy chain promoter (pVH), the intronic activator E.mu. upstream of said promoter of and the palindrome hs3a/hs1,2/hs3b downstream of said C.kappa. gene.

17. A homologous recombination targeting vector, which comprises a human class A immunoglobulin heavy chain constant region gene C.alpha. or a segment of said C.alpha. gene comprising at least an exon encoding the CH3 domain and a membrane exon, flanked by the sequences SEQ ID NO: 7 and SEQ ID NO: 8.

18. The targeting vector of claim 17, which comprises a cassette for expressing a selection marker, adjacent to said C.alpha. gene or to a segment of said gene.

19. The targeting vector of claim 18, wherein said expression cassette is flanked by site-specific recombination sequences.

20. The targeting vector of claim 19 wherein said sequences are LoxP sequences of Cre recombinase.

21. A mouse embryonic cell, which is modified with the targeting vector of claim 17.

22. A method for preparing humanized class IgA antibodies or fragments thereof, which comprises at least the following steps: a) immunizing the transgenic mouse of claim 1, and b) producing humanized class IgA antibodies or fragments of the antibodies from serum secretions or B lymphocytes of said transgenic mouse sacrificed beforehand.

Details for Patent 8,629,317

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2023-10-24
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2023-10-24
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2023-10-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.